

119TH CONGRESS
2^D SESSION

H. R. 8630

To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

APRIL 30, 2026

Mr. RULLI (for himself and Mrs. HARSHBARGER) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Protecting Equal Ac-
5 cess to Thyroid Act of 2026” or the “PEAT Act of 2026”.

1 **SEC. 2. PROHIBITION WITH RESPECT TO TREATMENT OF**
2 **PROTEINS IN BIOLOGICS.**

3 (a) **IN GENERAL.**—Section 351(i)(1) of the Public
4 Health Service Act (42 U.S.C. 262(i)(1)) is amended—

5 (1) by striking “The term” and inserting the
6 following:

7 “(A) The term”; and

8 (2) by adding at the end the following:

9 “(B) A biologic described in subparagraph
10 (A) may not be treated as a biological product
11 based solely on the presence of a protein that
12 is a clinically inactive component in such bio-
13 logic.”.

14 (b) **TECHNICAL CORRECTION.**—Section 351(i)(1) of
15 the Public Health Service Act (42 U.S.C. 262(i)(1)) is
16 amended in subparagraph (A), as designated by sub-
17 section (a)(1), by striking “protein ,” and inserting “pro-
18 tein,”.

○